KLARITROMITSIN (Clarithromycin).

     Synonyms : Binoklar, Klabaks, Klatsid, Kriksan, Fromilid, Crixan, Fromilid, Klabax, Klacid.

     White or not white crystalline powder. Almost nerastvorim in water, soluble in acetone, moderate-to ethanol and methanol.

     Semi antibiotic similar to the structure of erythromycin-6-O-metileritromitsin.

     It has a wide range of activity. Active against gram (staphylococci, streptococci, listerii, korinebakterii) and gram (meningokokki, Haemophilus wand, Campylobacter, Helicobacter pylori, etc.) bacteria, some anaerobov (receiver, bakteroidy, peptokokki), intracellular microorganisms (mycoplasma, legionelly, chlamydia and etc.), mycobacteria (except V.tuberculosis) and toksoplazm.

     When administered quickly and almost completely absorbed, T? at 3-7 h; well into the tissue and body fluid; biotransformation are in the liver, kidneys displayed.

     Assign with infection of the respiratory system, nose (including whooping cough), skin and soft tissue infections, and atypical mikobakteriozah (including AIDS); Also used in the treatment of gastric ulcers and duodenal ulcers associated with Helicobacter pylori.

     Applied inwards (in the form of tablets) and intravenously.

     Inside (not liquid) designate adults and children over 12 years of 0,5-1 g / day (1-2 admission); Children under 12 years - 7,5-15 mg / kg / day (up 0 , 5 g per day).

     Intravenous (drip) impose on 1 g / day (2 admission). The course of treatment 7-10 days.

     Possible side effects : diarrhoeal phenomenon psevdomembranozny colitis, insomnia, nightmares, holestaticheskaya jaundice, allergic reactions.

     The drug is not suitable for serious liver disease, porphyria, pregnancy and breastfeeding.

     As an inhibitor tsitohroma R-450 liver, increases the concentration in blood anti proximity, teofillina, carbamazepine, astemizola, tsizaprida, midazolama, cyclosporine, digoxin and other LS.

     Method of production : tablets of 0.25 g (N. 4, 7, 10, 14) and 0.5 g (No. 7, 14); Tablets ointment to 0.5 g (N. 5, 7); Granules (powder) to 2.5% suspension for receiving inside in vials of 1.5 and 2.5 g; dried powder for injection solutions in bottles of 0.5 g.

Materials allowed to copy only with the active hyperlink to the handbook of medicines